Actos (Pioglitazone) Cost in Indiana: Prices, Insurance, and Savings in 2026

What Pioglitazone Actually Costs in Indiana Right Now

The average cash price for a 30-day supply of generic pioglitazone at Indiana retail pharmacies sits around $15 in 2026. That figure reflects point-of-sale data across chain pharmacies like CVS, Walgreens, and Kroger locations statewide, along with independent pharmacies in Indianapolis, Fort Wayne, and Evansville.

Brand-name Actos carries a manufacturer list price of $60 per month from Takeda, but very few patients pay this amount. Generic pioglitazone tablets (15 mg, 30 mg, and 45 mg) have been available since the FDA approved the first generic formulations in 2012, and price competition among manufacturers like Mylan, Teva, and Dr. Reddy's has driven costs down significantly. A GoodRx or RxSaver coupon can push the price below $10 at select Indiana locations, particularly at Walmart and Costco pharmacies. Prices do fluctuate by ZIP code. A patient filling at an independent pharmacy in rural Bartholomew County may pay $18 to $22 without a coupon, while a Meijer pharmacy in Carmel might charge $12 for the same 30-tablet supply.

The price difference between the 15 mg and 45 mg tablets is negligible for generics. This matters because physicians sometimes titrate from 15 mg to 30 mg or 45 mg over 8 to 12 weeks depending on glycemic response, and patients can expect their out-of-pocket cost to remain stable across dose adjustments.

Indiana Medicaid Coverage for Pioglitazone

Indiana Medicaid, administered through managed care entities like Anthem, CareSource, and MDwise under the Hoosier Healthwise and Healthy Indiana Plan (HIP 2.0) programs, covers generic pioglitazone for its FDA-approved indication of type 2 diabetes mellitus. The drug sits on the Indiana preferred drug list as a Tier 2 generic.

Coverage does not extend to off-label prescribing for nonalcoholic steatohepatitis (NASH), now formally called metabolic dysfunction-associated steatohepatitis (MASH). This gap matters. The PIVENS trial (N=247) published in the New England Journal of Medicine demonstrated that pioglitazone 30 mg daily produced histologic improvement in NASH patients without diabetes, with 34% of pioglitazone-treated subjects meeting the primary endpoint versus 19% on placebo (Sanyal et al., NEJM 2010). The American Association for the Study of Liver Diseases (AASLD) practice guidance lists pioglitazone as a pharmacotherapy option for biopsy-confirmed NASH, yet Indiana Medicaid's formulary restriction means patients seeking this off-label use must appeal or pay out of pocket.

For Medicaid patients with type 2 diabetes, copays under HIP 2.0 range from $1 to $4 for preferred generics. Patients enrolled in traditional Hoosier Healthwise pay $0 for covered prescriptions. Prior authorization is generally not required for pioglitazone when prescribed for type 2 diabetes, though some managed care plans require documentation that metformin was tried first or is contraindicated. A denied claim can be appealed through the standard Indiana Medicaid fair hearing process within 30 days.

Insurance Coverage Beyond Medicaid

Most commercial insurance plans active in Indiana place generic pioglitazone on Tier 1 or Tier 2 of their formularies. Anthem Blue Cross Blue Shield, UnitedHealthcare, and Cigna plans sold through the federal marketplace (Indiana uses healthcare.gov) all list pioglitazone as a preferred generic for type 2 diabetes.

Typical copays on employer-sponsored plans range from $0 to $15 per month. High-deductible health plans (HDHPs) paired with health savings accounts require the patient to pay the negotiated rate until meeting their deductible. For pioglitazone, that negotiated rate usually falls between $8 and $20, depending on the pharmacy benefit manager. Express Scripts, CVS Caremark, and OptumRx each contract different rates with retail pharmacies across Indiana.

Medicare Part D plans also cover pioglitazone. Under the 2026 Part D redesign following the Inflation Reduction Act, out-of-pocket prescription costs are capped at $2,000 annually. For a drug costing $15 per month, pioglitazone alone would never approach that threshold. Most standalone Part D plans (Humana, SilverScript, AARP/UnitedHealthcare) assign pioglitazone to Tier 1 with copays between $0 and $10.

Indiana state employee health plans administered through the State Personnel Department include pioglitazone as a covered generic. The Endocrine Society's clinical practice guideline on type 2 diabetes pharmacotherapy endorses TZDs as second-line therapy after metformin, which supports formulary inclusion across payer categories.

Compounded Pioglitazone in Indiana

Compounded pioglitazone is legal in Indiana through licensed 503A compounding pharmacies. These pharmacies operate under Indiana Board of Pharmacy regulations and federal law (the Drug Quality and Security Act of 2013), which permits patient-specific compounding when a prescriber determines a medical need.

Why would someone compound a drug that already costs $15 as a generic tablet? A few scenarios apply. Some patients require a liquid suspension because they cannot swallow tablets (post-bariatric surgery, dysphagia, or feeding tube administration). Others need a dose not commercially available (e.g., 7.5 mg or 22.5 mg for slow titration or renal dose adjustment). Compounding pharmacies in Indiana such as Hoosier Compounding Pharmacy in Indianapolis and Custom Rx Shoppe in Fishers can prepare these formulations.

Pricing for compounded pioglitazone varies widely. Some 503A pharmacies have been reported to offer pioglitazone capsules at minimal cost as part of combination preparations. Patients should confirm that their compounding pharmacy holds a valid Indiana Board of Pharmacy license and verify whether their insurance plan covers compounded medications, as most commercial plans and Medicaid do not. The FDA's guidance on 503A compounding outlines the regulatory framework that Indiana pharmacies must follow.

Discount Programs and Savings Cards

Several pathways exist to reduce pioglitazone costs below the $15 average for Indiana residents who are uninsured or underinsured. Free discount cards are the simplest option.

GoodRx, RxSaver, and SingleCare each negotiate pharmacy-specific prices. At the time of writing, GoodRx lists pioglitazone 30 mg (#30 tablets) at $4.00 to $9.00 across Indianapolis-area pharmacies. Walmart's $4 generic list historically included pioglitazone, though availability varies by location and should be confirmed at the pharmacy counter. Costco's member pharmacy pricing is competitive, and a Costco membership is not required to fill prescriptions at their pharmacy under federal law, though non-members pay a small surcharge.

Takeda, the manufacturer of brand Actos, previously offered a savings card program. As of 2026, the brand savings card has limited availability given that the generic market dominates. Patients specifically prescribed brand Actos (rare, but some physicians prefer it for consistency) should contact Takeda's patient assistance line directly. For income-qualified patients, Takeda's patient assistance program and NeedyMeds both maintain pioglitazone-specific assistance options.

Mark Cuban Cost Plus Drugs (costplusdrugs.com) offers pioglitazone 30 mg at a transparent markup over manufacturing cost, typically under $5 for a 30-day supply with flat-rate shipping. Indiana patients using this mail-order option should factor in the 3-to-5-day shipping window when timing refills. The CDC's National Diabetes Statistics Report estimates 10.5% diabetes prevalence in Indiana (above the national average of 8.7%), underscoring the population-level importance of affordable access to medications like pioglitazone.

Telehealth Prescribing in Indiana

Indiana permits telehealth prescribing of pioglitazone. The state's telehealth parity law (Indiana Code 25-1-9.5) allows licensed prescribers to evaluate patients and write prescriptions via synchronous audio-video visits. Pioglitazone is not a controlled substance, so it faces none of the DEA-related telehealth prescribing restrictions that apply to medications like testosterone or stimulants.

Platforms like HealthRX, Cerebral, and PlushCare can connect Indiana residents with licensed physicians or nurse practitioners who can prescribe pioglitazone after a virtual evaluation. The prescriber must hold an active Indiana medical license or practice under the Interstate Medical Licensure Compact, which Indiana joined. A standard telehealth visit for diabetes management runs $50 to $150 without insurance, though many commercial plans cover telehealth at the same copay as in-person visits following pandemic-era policy changes that Indiana made permanent in 2021.

Prescriptions written via telehealth are transmitted electronically to any Indiana pharmacy. Patients can choose between a local retail pharmacy for same-day pickup or a mail-order pharmacy for potential cost savings. The American Diabetes Association Standards of Care (2024) explicitly supports telemedicine as a care delivery mechanism for diabetes management, including pharmacotherapy initiation and dose titration.

Clinical Considerations That Affect Cost Decisions

Pioglitazone's cost profile looks favorable, but clinical factors influence whether it remains the right choice over time, and those factors can alter the total cost of care.

The drug carries a black box warning for congestive heart failure. Patients in NYHA Class III or IV heart failure should not take pioglitazone. Weight gain of 2 to 4 kg is common in the first year of therapy, driven by fluid retention and adipocyte differentiation. This side effect may prompt physicians to add a diuretic (additional cost) or switch to an alternative agent like an SGLT2 inhibitor. Edema-related monitoring typically involves periodic BNP or NT-proBNP testing, adding $20 to $50 per lab draw.

Bone mineral density reduction has been documented in women taking pioglitazone long-term. The Women's Health Initiative observational analysis found increased fracture risk among postmenopausal women on TZD therapy. DEXA screening may be warranted, costing $50 to $150 out of pocket or covered under preventive benefits for women over 65.

A meta-analysis published in the BMJ examining pioglitazone and bladder cancer risk found a modest association with prolonged use exceeding 24 months (Filipova et al., 2018). The FDA reviewed this signal and concluded the evidence was inconclusive, keeping the drug on the market with label warnings. Indiana prescribers should discuss this risk with patients to inform shared decision-making.

For patients with type 2 diabetes who also carry a NASH/MASH diagnosis, pioglitazone offers dual benefit at a single-drug cost. The PIVENS trial showed statistically significant improvement in hepatic steatosis, lobular inflammation, and the NAFLD Activity Score with pioglitazone versus placebo (Sanyal et al., 2010). Given that dedicated MASH therapies like resmetirom (Rezdiffra) launched in 2024 at approximately $47,400 per year, pioglitazone at $15 per month ($180 per year) represents a 260-fold cost difference for a drug with proven histologic efficacy in this population.

How Indiana Compares to Neighboring States

Pioglitazone pricing in Indiana aligns closely with the broader Midwest market. Ohio, Illinois, Michigan, and Kentucky all show average cash-pay prices of $12 to $18 per month for generic pioglitazone. Medicaid coverage patterns differ slightly. Illinois Medicaid covers pioglitazone for both type 2 diabetes and NASH under a prior authorization pathway, while Indiana restricts coverage to the on-label diabetes indication only. Patients near the Indiana-Illinois border (Gary, Hammond, East Chicago) may benefit from checking Illinois pharmacy pricing, though Medicaid coverage is state-specific and not transferable.

The National Institute of Diabetes and Digestive and Kidney Diseases reports that Indiana ranks 13th nationally in age-adjusted diabetes prevalence. This high burden drives competitive generic pricing as pharmacies stock the drug in volume, keeping per-unit costs low relative to states with lower diabetes prevalence and lower dispensing volume.

Generic pioglitazone 45 mg, 30 tablets, at an Indiana Kroger pharmacy: $14.87 with a discount coupon as of May 2026.